Company intelligence / Profile preview

San Fu Biotech

Ownership: Private
Development stage: Other

Overview

San Fu Biotech is developing RGI-2001, a first-in-class small molecule immunomodulator licensed from REGiMMUNE, for the prophylaxis of acute Graft-versus-host disease. The drug has shown promising results in Phase 2 trials conducted by REGiMMUNE in the US. SFB plans to submit an IND application and conduct clinical trials in major Asian countries.

Therapeutic areas: OphthalmologyImmunologyOncology
Modalities: Small moleculeLiposomal formulation (for RGI-2001, a liposomal alpha-galactosylceramide analog)
Industry: Biotech

Partnerships

REGiMMUNE Limited – licensing agreement for RGI-2001 development and commercialization rights across major Asian countries

Beyond the preview

Go deeper on San Fu Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on San Fu Biotech.

Explore the full profile